Advancing the medical management of epilepsy: Disease modification and pharmacogenetics

Journal of Child Neurology

Volumn 17, Issue SUPPL. 1, 2002, Pages

  Glauser, Tracy A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 REDUCTASE; DIAZEPAM; DRUG METABOLIZING ENZYME; EPOXIDE HYDROLASE; ETHOSUXIMIDE; FELBAMATE; GLUTAMATE RECEPTOR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PHENOBARBITAL; PHENYTOIN; PREGNANE X RECEPTOR; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ANALYTICAL ERROR; ARTICLE; CHILDHOOD DISEASE; CLINICAL STUDY; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSPORT; EPILEPSY; EPILEPTOGENESIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN GENETICS; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SEIZURE; TREATMENT PLANNING; VERTIGO;

EID: 0036240388     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738020170011301     Document Type: Article

References (105)

1. Antiepileptogenic agents: How close are we?
2. Principles of drug treatment
3. Prognosis for total control of complex partial and secondarily generalized tonic-clonic seizures
4. Antiepileptic drugs
5. Patients with refractory seizures
6. Principles of treatment of patients with chronic active epilepsy
7. Measurement of anticonvulsants and their metabolites in biological fluids
8. Gas chromatographic analysis for anticonvulsant drugs in biologic fluids
9. General principles: Methods of determination of antiepileptic drugs
10. Disease modification in epilepsy
11. Is epilepsy a progressive disease? The neurobiological consequences of epilepsy
12. Excitatory amino acids as a final common pathway for neurologic disorders
13. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action
14. Topiramate
15. Age-dependent changes in long-term seizure susceptibility and behavior after hypoxia in rats
16. NBQX blocks acute and late epileptogenic effects of perinatal hypoxia
17. Topiramate blocks perinatal hypoxia-induced seizures in rat pups
18. Free radical scavenging enzyme activity profiles in risk assessment of idiosyncratic drug reactions
19. Free radical-mediated diseases in pediatrics
20. Definitions, properties, and reactions of radicals
21. Glutathione peroxidase deficiency and childhood seizures
22. Post-traumatic epilepsy: Cellular mechanisms and implications for treatment
23. Mechanism of action of biological antioxidants
24. Small molecule antioxidant defenses in human extracellular fluids
25. Biological functions of selenium
26. The anticonvulsant zonisamide scavenges free radicals
27. Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus
28. In vivo evaluation of hippocampal antioxidant ability of zonisamide in rats
29. Zonisamide reduces the increase in 8-hydroxy-2′-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats
30. Excitoprotective effect of felbamate in cultured cortical neurons
31. Neuroprotection with felbamate: A 7- and 28-day study in transient forebrain ischemia in gerbils
32. Idiosyncratic reactions: New methods of identifying high-risk patients
33. Clinical pharmacogenomics: Applications in pharmaceutical R&D
34. Extreme discordant phenotype methodology: An intuitive approach to clinical pharmacogenetics
35. Future directions for epilepsy research
36. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?
37. Advances in pharmacogenetics and pharmacogenomics
38. Pharmacokinetic principles of antiepileptic therapy in children
39. Pharmacokinetic principles of drug treatment
40. The role of active metabolites in drug toxicity
41. Mechanisms of drug reactions: The metabolic track
42. Antiepileptic drug mechanisms of action
43. The pharmacologic basis of antiepileptic drug action
44. Antiepileptic drug pharmacokinetics and interactions: Impact on treatment of epilepsy
45. Cytochrome P450-General features
46. Concise review of the cytochrome P450s and their roles in toxicology
47. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
48. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature
49. Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology
50. CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity
51. A novel single nucleotide polymorphism altering stability and activity of CYP2A6
52. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: Impairment of its promoter activity
53. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin
54. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population
55. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride in humans
56. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype
57. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502)
58. Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism
59. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
60. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid
61. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
62. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
63. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans
64. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
65. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
66. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism
67. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
68. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
69. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians
70. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin
71. Genetic polymorphism of human CYP2E1: Characterization of two variant alleles
72. A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake
73. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
74. Glutathione-S-transferase polymorphisms and their biological consequences
75. Metabolic polymorphisms
76. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics
77. Glucuronosyltransferases
78. Glutathione-S-transferase
79. Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue
80. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues
81. Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants
82. Epoxide hydrolase-polymorphism and role in toxicology
83. Induction of drug metabolising enzymes: Pharmacokinetic and toxicological consequences in humans
84. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor
85. Cyp3A regulation: From pharmacology to nuclear receptors
86. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors
87. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy
88. A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus-And prevalence of variants in patients with epilepsy
89. Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus
90. Possible association between childhood absence epilepsy and the gene encoding GABRB3
91. No association found between polymorphisms in genes encoding mGluR7 and mGluR8 and idiopathic generalised epilepsy in a case control study
92. Allelic association of juvenile absence epilepsy with a GluR5 kainate receptor gene (GRIK1) polymorphism
93. Antibiotic deafness and other topics
94. P-glycoprotein, a gatekeeper in the blood-brain barrier
95. MDR1 gene expression in brain of patients with medically intractable epilepsy
96. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy
97. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
98. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo